-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1000

Benzinga·07/21/2026 13:51:16
Listen to the news
Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $995 to $1000.